News
Public · Published
Argus Research maintains Eli Lilly at Buy, raises price target to $1550 from $1300
Argus Research kept a Buy rating on Eli Lilly and raised its price target to $1550 from $1300, a 19.2% increase. That target implies 12.8% upside from the October 29 close of $1373.70.
Published:
Updated:
What happened
Argus Research kept a Buy rating on Eli Lilly and raised its price target to $1550 from $1300, a 19.2% increase. That target implies 12.8% upside from the October 29 close of $1373.70.
Confirmed
Global impact / market context
A higher price target signals an analyst expects more future value from Eli Lilly. Investors often treat such changes as a sign of confidence, which can draw buying interest, though a target is an estimate, not a promise of returns.
Analyst inference
Other recent analyst targets for Eli Lilly range from $1316 to $1500, with mostly positive ratings. Argus now sits above that range, suggesting it is more optimistic than peers, which may shape how investors compare the stock's potential.
Analyst inference
What to watch
- Four analyst notes over the past 30 days put Eli Lilly price targets between $1316 and $1500. Confirmed
- Watch whether other analysts raise their own targets toward $1550, which would show broader confidence in the outlook. Proposed
- Track Eli Lilly's revenue and costs in coming reports, since weaker results could undercut the case for a higher target. Analyst inference
Evidence
- Original source link unavailable